Influence of autologous bone marrow stem cell transplantation on short-term heart function in cardiac failure patients

Qing-jun You,Zhen-ya Shen,Ming-di Xiao,Xi-chu Jiang

DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.08.018

2008-01-01

Abstract:AIM: The myocardial cells lost their ability of proliferation when human being is born. Current researches have focused on how to treat heart failure by supplying functional myocardial cells. This study showed the effect of mesenchymal stem cell transplantation on late heart function in patients with heart failure. METHODS: ①From October 2003 to June 2005, 23 patients with acute myocardial infarction were admitted at the Department of Cardiothoracic Surgery, Fourth Hospital, Soochow University into two groups randomly. 7 patients in experimental group were received bone marrow stem cell transplantation, while 16 patients in control group only cured with traditional way. At the same time, we took another 11 patients with severe rheumatic heart disease, severe bicuspid valve disease and heart failure into experimental group, and patients in experimental group were treated with bone marrow stem cell transplantation during the surgery of bicuspid valve replacement. Divided another 10 patients treated in the last 2 years with severe bicuspid valve disease and heart failure into control group, patients in control group were only performed bicuspid valve replacement. Above-mentioned patients received inotropic agent and diuretic agent to maintain heart function. Patients and their family members singed informed consents. The study was approved by Hospital Medical Ethics Committee. ② Bone marrow (25 mL) was aseptically collected from anterosuperior iliac spine. Bone marrow stem cells were generally taken from bone marrow,isolated and cultivated in DMEM medium. Cells of 80% confluence were passaged by trypsinization. Three passage of cells were used for transplantation at 1.5×1010 L-1. In experimental myocardial infarction group, we perfused 5 mL mesenchymal stem cells into the heart by coronary artery. Patients in the control myocardial infarction group only received routine therapy. While in experimental bicuspid valve disease group, 5 mL mesenchymal stem cells were perfused through coronary artery and injected into different parts of myocardium directly, 0.1-0.2 mL at each point, with an interval of 2 cm. Patients in the mitral lesion control group received replacement of mitral valve. ③Heart function was assessed by ultrasonic cardiography and radionuclide imaging. RESULTS: All patients were followed up for 3 months. ①Compared to the control group, patients in experimental myocardial infarction group got significant improvement in cardiac output (CO), ejection fraction (EF) and myocardial infarct size 10 days before the surgery and 2 weeks after the surgery (P > 0.05). EF and CO were significantly elevated at week 4, 6 and 8 after the surgery (P < 0.01), and myocardial infarct size was shortened (P < 0.01). ②Compared to the control group, EF and CO were significantly elevated at week 4 after the surgery in the experimental bicuspid valve disease group (t =3.97,P < 0.01;t =3.61,P < 0.01), and significantly at week 8 (t =2.91,P < 0.05;t =2.64,P < 0.05). CONCLUSION: Autologous bone marrow stem cell transplantation can improve heart function of patients with coronary atherosclerotic heart disease heart failure, so does in patients with rheumatic mitral valve and cardiac failure.